Gilead Sciences (NASDAQ:GILD – Get Free Report) and TG Therapeutics (NASDAQ:TGTX – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.
Institutional and Insider Ownership
83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Gilead Sciences has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Gilead Sciences | -12.47% | -1.85% | -0.61% |
| TG Therapeutics | 11.81% | 18.82% | 7.78% |
Valuation and Earnings
This table compares Gilead Sciences and TG Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gilead Sciences | $29.44 billion | 7.15 | $8.51 billion | ($3.16) | -53.71 |
| TG Therapeutics | $616.29 million | 16.13 | $447.18 million | $0.66 | 99.64 |
Gilead Sciences has higher revenue and earnings than TG Therapeutics. Gilead Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for Gilead Sciences and TG Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gilead Sciences | 0 | 6 | 23 | 0 | 2.79 |
| TG Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Gilead Sciences currently has a consensus price target of $170.15, suggesting a potential upside of 0.25%. TG Therapeutics has a consensus price target of $63.00, suggesting a potential downside of 4.20%. Given Gilead Sciences’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Gilead Sciences is more favorable than TG Therapeutics.
Summary
TG Therapeutics beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
About TG Therapeutics
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions. The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
